[HTML][HTML] Prevalence of long-acting injectable antipsychotic use in Canadian early intervention services for psychosis
KA McKee, CE Crocker, K Dikaios, N Otter… - Journal of Psychiatric …, 2023 - Elsevier
The use of long-acting injectable (LAI) antipsychotic drugs for psychotic disorders in Canada
has been historically low compared to other jurisdictions despite advantages of LAIs in …
has been historically low compared to other jurisdictions despite advantages of LAIs in …
Barriers to long‐acting injectable atypical antipsychotic use in Japan: Insights from a comparative psychiatrist survey
Y Oguchi, N Miyake, K Ando - Neuropsychopharmacology …, 2024 - Wiley Online Library
Aims To investigate the negative attitudes of Japanese psychiatrists toward atypical long‐
acting injectable (LAI) antipsychotics, which are the current mainstream LAIs in Japan …
acting injectable (LAI) antipsychotics, which are the current mainstream LAIs in Japan …
[PDF][PDF] Psychoeducation on adherence to treatment of schizophrenia patient during covid-19 pandemic era
PY Putra, I Fithriyah - Indian Journal of Forensic Medicine & …, 2021 - researchgate.net
Abstract Background: The outbreak of Covid-19 is really disrupting people's thought and
their ability to face the problem clearly and their mental health could be disturbed. They will …
their ability to face the problem clearly and their mental health could be disturbed. They will …
Duration of long‐acting injectable antipsychotic treatment and reasons for its discontinuation: A chart review of patients with schizophrenia.
T Kishi, K Sakuma, M Okuya… - Psychiatry & Clinical …, 2021 - search.ebscohost.com
A smaller proportion of patients who discontinued LAI-AP in less than 6 months in patients
received who AOM compared to patients received RIS-LAI (IP i < 0.01). Nineteen patients …
received who AOM compared to patients received RIS-LAI (IP i < 0.01). Nineteen patients …